Graves’ Orbitopathy: Report of 82 cases
##plugins.themes.academic_pro.article.main##
Abstract
Abstract :
Introduction: Graves’ disease (GD) is a common autoimmune disorder. Graves’orbitopathy (GO) is its most common extrathyroidal manifestation. It is rare but may reveal the disease.
Aim: To describe the demographic, clinical and therapeutic features of GO.
Methods: We carried out a retrospective and descriptive analysis of 82 patients with GO. This study was conducted in Ophthalmology and Endocrinology departments of Taher Sfar University Hospital in Mahdia, between January 2010 and December 2017. GD patients diagnosed with GO were included.
Results: The mean age was 36.17 years ± 12.81. Patients aged 19-40 years had the highest rate of GO. The male-to-female ratio was 0.49. Family history of autoimmune thyroid disease was present in 15% and associated autoimmune disease in 4% of cases. Smoking was seen in 71% of patients. The onset of GO was simultaneous with onset of GD in 45%, before in 21% and after the onset of GD in 34% of cases. GO was bilateral in 76% of patients. The most common ocular symptoms were prominent eyes (55% of patients), ocular pain (11%) and diplopia (41%). Proptosis and upper eyelid retraction were the most common clinical signs (93% and 90% respectively). Dysthyroid optic neuropathy was present in one eye, keratitis in one eye and glaucoma in five eyes. Severe disease was noted in 11% and active disease was present in 7% of patients. CT-scan and magnetic resonance imaging scan (MRI) were performed in 48% and 42% of cases respectively. Proptosis was the most common radiological sign. Thyroid dysfunction was managed with anti-thyroid medication only (59%), thyroxine replacement (37%), radioactive iodine (35%) and thyroidectomy (6%). 20% of patients received corticosteroids. One patient required immunosuppressive therapy.
Conclusion: GO is a complex disease, which is associated with impaired quality of life and can potentially result in sight-threatening complications. Appropriate diagnosis, convenient therapy and a regular follow-up are necessary to improve results and avoid the aesthetic and functional sequelae.
Keywords:
Hyperthyroidism; Graves' disease; Proptosis; Thyroid associated orbitopathy##plugins.themes.academic_pro.article.details##
References
- Références 1. Gillespie EF, Smith TJ, Douglas RS. Thyroid Eye Disease: Towards an Evidence Base for Treatment in the 21st Century. Curr Neurol Neurosci Rep 2012;12(3):318‑24. 2. Leray B, Imbert P, Thouvenin D, Boutault F, Caron P. Prise en charge diagnostique et thérapeutique d'une orbitopathie dysthyroïdienne : une affection multidisciplinaire. J Fr Ophtalmol 2013;36(10):874‑85. 3. Bartley GB, Gorman CA. Diagnostic Criteria for Graves' Ophthalmopathy. Am J Ophthalmol 1995;119(6):792‑5. 4. Mourits MPh, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol (Oxf) 1997;47(1):9‑14. 5. Werner SC. Modification of the Classification of the Eye Changes of Graves' Disease. Am J Ophthalmol 1977;83(5):725‑7. 6. Kahaly GJ, Bartalena L, Hegedüs L, Leenhardt L, Poppe K, Pearce SH. 2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism. Eur Thyroid J 2018;7(4):167‑86. 7. Brix TH, Kyvik KO, Christensen K, Hegedüs L. Evidence for a major role of heredity in Graves' disease: a population-based study of two Danish twin cohorts. J Clin Endocrinol Metab 2001;86(2):930‑4. 8. Inaba H, De Groot LJ, Akamizu T. Thyrotropin Receptor Epitope and Human Leukocyte Antigen in Graves' Disease. Front Endocrinol 2016;7:120. 9. Reddy SVB, Jain A, Yadav SB, Sharma K, Bhatia E. Prevalence of Graves' ophthalmopathy in patients with Graves' disease presenting to a referral centre in north India. Indian J Med Res 2014;139(1):99‑104. 10. Ackuaku-Dogbe E, Akpalu J, Abaidoo B. Epidemiology and clinical features of thyroid-associated orbitopathy in Accra. Middle East Afr J Ophthalmol 2017;24(4):183. 11. Lim NCS, Sundar G, Amrith S, Lee KO. Thyroid eye disease: a Southeast Asian experience. Br J Ophthalmol 2015;99(4):512‑8. 12. Li Q, Ye H, Ding Y, Chen G, Liu Z, Xu J, et al. Clinical characteristics of moderate-to-severe thyroid associated ophthalmopathy in 354 Chinese cases. Soares P, éditeur. PLOS ONE 2017;12(5):e0176064. 13. Perros P, Žarković M, Azzolini C, Ayvaz G, Baldeschi L, Bartalena L, et al. PREGO (presentation of Graves' orbitopathy) study: changes in referral patterns to European Group On Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012. Br J Ophthalmol 2015;99(11):1531‑5. 14. Perros P, Hegedüs L, Bartalena L, Marcocci C, Kahaly GJ, Baldeschi L, et al. Graves' orbitopathy as a rare disease in Europe: a European Group on Graves' Orbitopathy (EUGOGO) position statement. Orphanet J Rare Dis [Internet] déc 2017 [cité 23 sept 2018];12(1). Disponible sur: http://ojrd.biomedcentral.com/articles/10.1186/s13023-017-0625-1 15. Bartley GB, Fatourechi V, Kadrmas EF, Jacobsen SJ, Ilstrup DM, Garrity JA, et al. The incidence of Graves' ophthalmopathy in Olmsted County, Minnesota. Am J Ophthalmol 1995;120(4):511‑7. 16. Chabchoub G, Mnif M, Maalej A, Charfi N, Ayadi H, Abid M. Étude épidémiologique des maladies autoimmunes thyroïdiennes dans le sud tunisien. Ann Endocrinol 2006;67(6):591‑5. 17. Mellington FE, Dayan CM, Dickinson AJ, Hickey JL, MacEwen CJ, McLaren J, et al. Management of thyroid eye disease in the United Kingdom: A multi-centre thyroid eye disease audit Orbit. 2017;36(3):159‑69. 18. Lavard L, Ranløv I, Perrild H, Andersen O, Jacobsen BB. Incidence of juvenile thyrotoxicosis in Denmark, 1982-1988. A nationwide study. Eur J Endocrinol 1994;130(6):565‑8. 19. Birrell G, Cheetham T. Juvenile thyrotoxicosis; can we do better? Arch Dis Child 2004;89(8):745‑50. 20. Eha J, Pitz S, Pohlenz J. Clinical features of pediatric Graves' orbitopathy. Int Ophthalmol 2010;30(6):717‑21. 21. Bahn RS. Current Insights into the Pathogenesis of Graves' Ophthalmopathy. Horm Metab Res Horm Stoffwechselforschung Horm Metab 2015;47(10):773‑8. 22. Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C, et al. Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 2008;158(3):273‑85. 23. Träisk F, Tallstedt L, Abraham-Nordling M, Andersson T, Berg G, Calissendorff J, et al. Thyroid-associated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab 2009;94(10):3700‑7. 24. Bartalena L, Piantanida E. Cigarette smoking: number one enemy for Graves ophthalmopathy. Pol Arch Med Wewn 28 2016;126(10):725‑6. 25. Thornton J, Kelly SP, Harrison RA, Edwards R. Cigarette smoking and thyroid eye disease: a systematic review. Eye Lond Engl 2007;21(9):1135‑45. 26. Vestergaard P. Smoking and thyroid disorders--a meta-analysis. Eur J Endocrinol 2002;146(2):153‑61. 27. Wiersinga WM, Smit T, van der Gaag R, Mourits M, Koornneef L. Clinical presentation of Graves' ophthalmopathy. Ophthalmic Res 1989;21(2):73‑82. 28. Saeed P, Tavakoli Rad S, Bisschop PHLT. Dysthyroid Optic Neuropathy: Ophthal Plast Reconstr Surg 2018;1. 29. Lee JH, Lee SY, Yoon JS. Risk factors associated with the severity of thyroid-associated orbitopathy in Korean patients. Korean J Ophthalmol KJO 2010;24(5):267‑73. 30. Fishman DR, Benes SC. Upgaze intraocular pressure changes and strabismus in Graves' ophthalmopathy. J Clin Neuroophthalmol 1991;11(3):162‑5. 31. Strianese D. Update on Graves disease: advances in treatment of mild, moderate and severe thyroid eye disease. Curr Opin Ophthalmol 2017;28(5):505‑13. 32. Wiersinga WM, Perros P, Kahaly GJ, Mourits MP, Baldeschi L, et al. Clinical assessment of patients with Graves' orbitopathy: the European Group on Graves' Orbitopathy recommendations to generalists, specialists and clinical researchers. Eur J Endocrinol 2006;155(3):387‑9. 33. Fidor-Mikita E, Krupski W. Computed tomography imaging of orbits in thyroid orbitopathy 2(1):5. 34. Ben Simon GJ, Katz G, Zloto O, Leiba H, Hadas B, Huna-Baron R. Age differences in clinical manifestation and prognosis of thyroid eye disease. Graefes Arch Clin Exp Ophthalmol 2015;253(12):2301‑8. 35. Tanda ML, Piantanida E, Liparulo L, Veronesi G, Lai A, Sassi L, et al. Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed graves' hyperthyroidism seen at a single center. J Clin Endocrinol Metab 2013;98(4):1443‑9. 36. Bartalena L, Pinchera A, Marcocci C. Management of Graves' ophthalmopathy: reality and perspectives. Endocr Rev 2000;21(2):168‑99. 37. Meier DA, Brill DR, Becker DV, Clarke SEM, Silberstein EB, Royal HD, et al. Procedure guideline for therapy of thyroid disease with (131)iodine. J Nucl Med Off Publ Soc Nucl Med 2002;43(6):856‑61. 38. Mumtaz M, Lin LS, Hui KC, Mohd Khir AS. Radioiodine I-131 For The Therapy Of Graves' Disease. Malays J Med Sci MJMS 2009;16(1):25‑33. 39. Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, et al. The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy. Eur Thyroid J 2016;5(1):9‑26. 40. Kahaly GJ, Pitz S, Hommel G, Dittmar M. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy. J Clin Endocrinol Metab 2005;90(9):5234‑40. 41. Marcocci C, Bartalena L, Panicucci M, Marconcini C, Cartei F, Cavallacci G, et al. Orbital cobalt irradiation combined with retrobulbar or systemic corticosteroids for Graves' ophthalmopathy: a comparative study. Clin Endocrinol (Oxf) 1987;27(1):33‑42.